CD46 and cancer: Overall, these studies highlight the critical roles of IL6 and IL6R, as well as CD46 and JAG1, in the survival and invasive capacity of cancer cells, and their broad promise as targets for antitumor therapies, as well as exploring the possibility of combining them with other therapeutic agents.